A First-in-Human SAD/MAD Study to Evaluate Safety, Tolerability and PK of ENC0653 Ointment in Healthy Adult Subjects
3d agoen
From the article
Conditions : Healthy Interventions : Drug: Low Dose, 10%BSA; Drug: Low Dose, 20%BSA; Drug: Middle Dose, 20%BSA; Drug: High Dose, 20%BSA; Drug: Low Dose, 20%BSA; Drug: Middle Dose, 20%BSA; Drug: High Dose, 20%BSA; Drug: Placebo Sponsors : EnnovaBio Recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Anixa Biosciences Aktie: Höchste Lira-cel-Dosis erreicht
aktiencheck.de
Life Biosciences Begins First Human Trial of Cellular Rejuvenation Drug for Age-Related Vision Loss
Life Biosciences has dosed the first human patient with ER-100, a cellular rejuvenation therapy designed to reverse age-related sight loss b
wired.com·24d ago10 Rekomendasi Serum dengan Niacinamide, Kuatkan Skin Barrier dan Samarkan Bekas Jerawat
cantika.com·5h ago
Un nuevo estudio Relaciona mayor vitamina C con mejor salud cerebral en adultos mayores
Infobae·4d ago
Cybin: 51 Prozent Plus auf Monatssicht
aktiencheck.de
CELEX:32026R1421: RĂšglement dâexĂ©cution (UE) 2026/1421 de la Commission du 30 juin 2026 modifiant le rĂšglement dâexĂ©cution (UE) no 540/2011 en ce qui concerne la prolongation de la pĂ©riode dâapprobation des substances actives bensulfuron, benzovindiflupyr
europol.europa.eu·8d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.